Epistatic effect of plasminogen activator inhibitor 1 and β-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: Interaction with environmental/clinical factors

Arthritis and Rheumatism

Volumn 56, Issue 5, 2007, Pages 1608-1617

  Gong, Rujun ^a   Liu, Zhihong ^a,b   Li, Leishi ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ANALYSIS; GENETIC EPISTASIS; GENETIC VARIABILITY; GENOTYPE; GLOMERULAR MICROTHROMBOSIS; GLOMERULOPATHY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; VALIDATION STUDY;

ADOLESCENT; ADULT; ALLELES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EPISTASIS, GENETIC; FEMALE; FIBRINOGEN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY GLOMERULUS; LOGISTIC MODELS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; THROMBOSIS;

EID: 34248545086     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22598     Document Type: Article

References (51)

1. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330: 1871-9.
2. D'Cruz DP. Systemic lupus erythematosus. BMJ 2006;332:890-4.
3. Lewis EJ, Schwartz MM. Pathology of lupus nephritis. Lupus 2005;14:31-8.
4. Kant KS, Pollak VE, Weiss MA, Glueck HI, Miller AN, Hess EV. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) 1981;60:71-86.
5. Miranda JM, Garcia Torres R, Jara LJ, Medina F, Cervera H, Fraga A. Renal biopsy in SLE: significance of glomerular thrombosis; analysis of 108 cases. Lupus 1994;3:25-9.
6. Pollak VE. Glomerular thrombosis predicts progression of glomerulonephritis: can we prevent progression? Am J Kidney Dis 1995;26:535-40.
7. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994;4: 1499-515.
8. Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis 1992;20:463-71.
9. Perdiguero M, Boronat M, Marco P, Rivera F. The role of antiphospholipid antibodies in lupus nephropathy. Nephron 1995; 71:35-9.
10. Frampton G, Hicks J, Cameron JS. Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int 1991;39:1225-31.
11. Kleinknecht D, Bobrie G, Meyer O, Noel LH, Callard P, Ramdane M. Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transplant 1989;4:854-8.
12. Bhandari S, Harnden P, Brownjohn AM, Turney JH. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. Q J Med 1998;91:401-9.
13. Abu-Shakra M, Urowitz MB, Gladman DD, Ritchie S. The significance of anticardiolipin antibodies in patients with lupus nephritis. Lupus 1996;5:70-3.
14. Fofi C, Cuadrado MJ, Godfrey T, Abbs I, Khamashta MA, Hughes GR. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin Exp Rheumatol 2001; 19:75-7.
15. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology (Am Soc Hematol Educ Program) 2005;:1-12.
16. Humphries SE, Green FR, Temple A, Dawson S, Henney A, Kelleher CH, et al. Genetic factors determining thrombosis and fibrinolysis. Ann Epidemiol 1992;2:371-85.
17. Kruithof EK. Plasminogen activator inhibitors: a review. Enzyme 1988;40:113-21.
18. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004;91:861-72.
19. Kwaan HC, Nabhan C. Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003;17:103-14.
20. Standeven KF, Ariens RA, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005;19: 275-88.
21. Thomas AE, Green FR, Kelleher CH, Wilkes HC, Brennan PJ, Meade TW, et al. Variation in the promoter region of the β fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers. Thromb Haemost 1991;65:487-90.
22. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004;103:1728-34.
23. Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke 2003;34:886-91.
24. Jood K, Ladenvall P, Tjarnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005;36:2077-81.
25. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001;104:3063-8.
26. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998;80:956-60.
27. Renner W, Cichocki L, Forjanics A, Koppel H, Gasser R, Pilger E. G-455A polymorphism of the fibrinogen β gene and deep vein thrombosis. Eur J Clin Invest 2002;32:755-8.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
29. Harris EN. Special report: the Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94:476-84.
30. Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. 2nd ed. New York: Igaku-Shoin; 1995.
31. Gong R, Liu Z, Li L. Mannose-binding lectin gene polymorphism associated with the patterns of glomerular immune deposition in IgA nephropathy. Scand J Urol Nephrol 2001;35:228-32.
32. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150-7.
33. Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modeling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2006;2:318-28.
34. Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics 2004;5:49.
35. Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 2002;11:2463-8.
36. Frankel WN, Schork NJ. Who's afraid of epistasis? Nat Genet 1996;14:371-3.
37. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30.
38. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis: a systematic review of clinical studies. Thromb Haemost 2005;94:362-5.
39. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005;25:1321-4.
40. Viles-Gonzalez JF, Fuster V, Badimon JJ. Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. Am Heart J 2005;149:S19-31.
41. Chu AJ. Tissue factor mediates inflammation. Arch Biochem Biophys 2005;440:123-32.
42. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32 Suppl 1:49-60.
43. Yang X, Chen X, Xu Q. Effects of low-molecular-weight heparin on proliferative glomerulonephritis. Zhonghua Nei Ke Za Zhi 1997;36:731-5.
44. Soria JM, Fontcuberta J. New approaches and future prospects for evaluating genetic risk of thrombosis. Haematologica 2005;90: 1212-22.
45. Franco RF, Reitsman PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-84.
46. Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science 2002;298:2345-9.
47. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356-60.
48. Montgomery HE, Clarkson P, Nwose OM, Mikailidis DP, Jagroop IA, Dollery C, et al. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the β-fibrinogen gene. Arterioscler Thromb Vasc Biol 1996;16: 386-91.
49. Carlborg O, Jacobsson L, Ahgren P, Siegel P, Andersson L. Epistasis and the release of genetic variation during long-term selection. Nat Genet 2006;38:418-20.
50. Cho YM, Ritchie MD, Moore JH, Park JY, Lee KU, Shin HD, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with type 2 diabetes mellitus. Diabetologia 2004;47:549-54.
51. Mannila MN, Eriksson P, Ericsson CG, Hamsten A, Silveira A. Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction. Thromb Haemost 2006;95:420-7.